Pfizer's Dividend Yield Is One of the Highest in the S&P 500. Here's Why the Dividend Is Safer Than It Might Seem
Pfizer has a plan to bounce back from recent obstacles.
Pfizer's dividend yield stands out among the S&P 500's top performers. Despite challenges, the pharmaceutical giant's safety and growth potential make it an appealing income stock. Reduced demand for coronavirus products impacted Pfizer's revenue, with Comirnaty sales down 32% and Paxlovid revenue plummeting 95% year-over-year. However, Pfizer's total revenue increased by 3% to $15 billion, surpassing expectations in nine out of the past 10 quarters.
The company has overcome patent exclusivity losses from Eliquis, Ibrance, and Xtandi, with newer and acquired products generating $13 billion in annualized sales and growing at a compound rate of 20% year-over-year. Pfizer's cost-cutting measures, totaling $7.2 billion over three years, further strengthen its financial position.
Despite the dividend's 5.8% forward yield, Pfizer's commitment to increasing payouts by 10.26% over the past five years demonstrates management's dedication to returning capital to shareholders. Additionally, Pfizer's pipeline, boasting 16 products in Phase 3 studies and numerous promising candidates, positions the company for future growth, even if clinical setbacks occur.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
